Cargando…
Pembrolizumab‐induced secondary sclerosing cholangitis in a non‐small cell lung cancer patient
A 50‐year‐old woman with stage IV lung adenocarcinoma received seven cycles of pembrolizumab as third‐line chemotherapy. Following the failure of pembrolizumab, she commenced fourth‐line chemotherapy of docetaxel and ramucirumab. The patient complained of epigastric pain and a computed tomography (C...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley & Sons, Ltd
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7148160/ https://www.ncbi.nlm.nih.gov/pubmed/32284868 http://dx.doi.org/10.1002/rcr2.560 |